- Market Capitalization, $K 115,643,832
- Shares Outstanding, K 2,521,671
- Annual Sales, $ 45,310 M
- Annual Income, $ 7,081 M
- 60-Month Beta 0.56
- Price/Sales 2.56
- Price/Cash Flow 8.48
- Price/Book 1.53
|Period||Period Low||Period High||Performance|
| || |
-2.28 (-4.74%)since 01/06/23
| || |
+2.24 (+5.14%)since 11/04/22
| || |
-6.22 (-11.94%)since 02/04/22
SNY earnings call for the period ending December 31, 2022.
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
|3rd Resistance Point||46.82|
|2nd Resistance Point||46.41|
|1st Resistance Point||46.13|
|1st Support Level||45.45|
|2nd Support Level||45.04|
|3rd Support Level||44.77|